Eravacycline

ArtNr	HY-16980-100mg
Hersteller	MedChem Express
CAS-Nr.	1207283-85-9
Menge	100 mg
Quantity options	100 mg 10 mg 1 ea 25 mg 5 mg
Kategorie	Reagents & Chemicals Biochemicals
Typ	Chemicals
Specific against	other
Purity	99.98
Citations	[1]Seifert H, et al. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents. 2017 Jul 10.\|[2]Zhao M, et al. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model. Antimicrob Agents Chemother. 2017 Jun 27;61(7).\|[3]Xiao XY, et al. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J Med Chem. 2012 Jan 26;55(2):597-605.\|[4]Sutcliffe JA, et al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58.\|[5]Grossman TH, et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59(5):2567-71. Ann Lab Med. 2021 May 1;41(3):293-301. Antibiotics (Basel). 2022 Sep 23;11(10):1298. Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. Antimicrob Agents Chemother. 2021 May 18;65(6):e00203-21. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112023. Clin Exp Pharmacol Physiol. 2023 Jul;50(7):604-609. Diagn Micr Infec Dis. 2020 Nov;98(3):115129. Infect Drug Resist. 2023 Apr 17:16:2271-2279. Infect Drug Resist. 2023 Sep 8:16:6005-6015. J Antibiot (Tokyo). 2019 Aug;72(8):600-604. J Antibiot (Tokyo). 2022 Sep;75(9):498-508. J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. J Clin Microbiol. 2020 Jan 28;58(2):e01603-19. Microbiol Spectr. 2023 Feb 14;11(1):e0323822. Microbiol Spectr. 2023 Jun 15;11(3):e0071823. Nat Microbiol. 2023 Mar;8(3):410-423. Nat Struct Mol Biol. 2023 Sep;30(9):1380-1392. Virulence. 2022 Dec;13(1):77-88. ACS Infect Dis. 2024 Dec 13;10(12):4127-4136. Biomaterials. 2024 Sep 11:314:122815. Cureus. 2024 Dec 1;16(12):e74917. J Antibiot (Tokyo). 2025 May;78(6):370-379. J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. mBio. 2021 Jun 29;12(3):e0103121. Microb Pathog. 2020 Dec;149:104502. Microbiol Spectr. 2025 Oct 16:e0160325. Pharmaceutics. 2021 Dec 5;13(12):2085. Research Square Preprint. 2022 Feb.
Smiles	O=C(NC(C(O)=C1C2=O)=CC(F)=C1C[C@@]3([H])C[C@@]4([H])[C@H](N(C)C)C(O)=C(C(N)=O)C([C@@]4(O)C(O)=C32)=O)CN5CCCC5
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	TP-434
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Antibiotic; Bacterial; Beta-lactamase
Manufacturer - HS Code	H302-H312-H332
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, sealed storage, away from moisture)
Molecular Weight	558.56
Product Description	Eravacycline is a potent and broad-spectrum antibacterial agent.
Manufacturer - Research Area	Infection
Solubility	10 mM in DMSO
Manufacturer - Pathway	Anti-infection
Clinical information	Launched
Isoform	Tetracycline
UNSPSC Code	12352005
Precautionary	P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P501

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.